|Bid||0.0000 x 1100|
|Ask||0.0000 x 1300|
|Day's Range||2.2450 - 2.3300|
|52 Week Range||1.5100 - 4.3900|
|Beta (5Y Monthly)||1.54|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Can-Fite BioPharma (NYSE: CANF) has completed pre-clinical studies demonstrating that a Cannabidiol (CBD)-rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth. The company's lead drug candidate Namodenoson is expected to enter the Phase 3 study in Q4 2021. The studies showed that CBD-rich T3/C15 cannabis fraction inhibited the growth of liver HEP-3b hepatocellular carcinoma cells via the A3AR by inhibiting Wnt- and NF-kappa B-related regulatory pathways. The Wnt signaling pathway is known to be highly active in controlling the growth of liver cancer cells. The company has filed patent applications for cannabinoid-based therapies where the A3AR target is overexpressed, including liver cancer. Price Action: CANF shares are down 1.7% at $2.41 in the market session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaSorrento Therapeutics To Buy ACEA Therapeutics For M In StockElectroCore's Stock Is Trading Higher After Its Nerve Stimulator Wins Canadian Approval For Migraine© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the six existing distribution agreements it has signed for its advanced stage drug candidates Piclidenoson and Namodenoson in select territories have remaining potential milestone payments of up to approximately $130 million plus double digit royalties on net sales following regulatory approval. In addition, to date, the Company has collected over $20 million in non-dilutive upfront and milestone payments.